Melanocortin Receptor Agonist (MC3R/MC4R)
PT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist derived from the α-melanocyte-stimulating hormone (α-MSH) analog melanotan II. It was developed by Palatin Technologies and received FDA approval in June 2019 under the trade name Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women — making it the first and only FDA-approved medication that works through the central nervous system to enhance sexual desire. The development of PT-141 arose from an unexpected observation during melanotan II research. Melanotan II, designed as a sunless tanning agent via melanocortin receptor activation, was found to produce sexual arousal as a side effect. PT-141 was subsequently engineered to retain the sexual arousal properties through MC3R/MC4R agonism while reducing the melanogenic (tanning) activity mediated by MC1R. The cyclic structure — a seven-amino-acid ring formed by a lactam bridge between Asp and Lys residues — confers metabolic stability and receptor selectivity. PT-141 represents a fundamentally different pharmacological approach to sexual dysfunction compared to PDE5 inhibitors (sildenafil, tadalafil). While PDE5 inhibitors act peripherally on vascular smooth muscle to facilitate erection, PT-141 acts centrally in the hypothalamus to initiate sexual arousal and desire through melanocortin-mediated dopamine release. This central mechanism means PT-141 addresses desire — not just the physical mechanics — making it effective in populations where PDE5 inhibitors fail.
Works through hypothalamic melanocortin receptors to initiate desire and arousal — not peripheral vasodilation.
The only FDA-approved centrally-acting medication for hypoactive sexual desire disorder (2019).
MC3R/MC4R activation produces arousal responses in both male and female research models through shared hypothalamic pathways.
Stimulates dopamine release in the medial preoptic area (MPOA) — the hypothalamic center for sexual motivation and reward.
Demonstrates efficacy in populations where PDE5 inhibitors are ineffective due to its non-vascular mechanism.
Single pre-activity dose with onset within 45 minutes — no daily regimen required.
PT-141 selectively activates melanocortin 3 (MC3R) and melanocortin 4 (MC4R) receptors in the central nervous system, particularly within the hypothalamic paraventricular nucleus (PVN) and medial preoptic area (MPOA). Upon binding, these GPCRs activate Gαs-coupled adenylyl cyclase, increasing cAMP and triggering downstream signaling cascades that culminate in dopamine release from hypothalamic neurons. The MC4R pathway is the primary mediator of PT-141's sexual arousal effects. MC4R activation in the PVN stimulates oxytocinergic neurons that project to the spinal cord, activating sacral parasympathetic centers controlling genital blood flow and arousal responses. Simultaneously, MC4R activation in the MPOA triggers dopaminergic signaling in the mesolimbic reward pathway, promoting sexual motivation and desire — the subjective "wanting" component of arousal. The MC3R component provides additional modulation through its role in reward processing and arousal state regulation. MC3R knockout models show reduced sexual motivation, suggesting this receptor contributes to the desire component independently of MC4R. The dual MC3R/MC4R agonism thus produces both physiological arousal (MC4R-oxytocinergic-parasympathetic) and psychological desire (MC4R/MC3R-dopaminergic-reward). This distinguishes PT-141 from PDE5 inhibitors, which only address the peripheral vascular component without influencing central desire pathways. The onset of effect (approximately 45 minutes post-injection) reflects the time required for central melanocortin receptor activation, downstream dopamine release, and establishment of pro-arousal neural signaling.
RECONNECT phase 3 trials (n=1,247) demonstrated significant improvement in desire and associated distress in premenopausal women.
Phase 3 Complete / FDA ApprovedPhase 2 studies showed pro-erectile effects independent of PDE5 inhibition — effective in PDE5-inhibitor non-responders.
Phase 2 CompleteTool compound for studying MC3R/MC4R pathways in reward, motivation, energy homeostasis, and inflammation.
ActiveMechanistic studies on melanocortin-driven dopamine signaling in the MPOA and mesolimbic pathway.
ActivePreclinical research on melanocortin agonism for blood pressure restoration and organ protection in hemorrhage models.
Preclinical| Period | Dose | Frequency | Notes |
|---|---|---|---|
| As needed | 1.75 mg | On-demand (SC) | FDA-approved dose — administer ~45 min before desired effect |
| Research range | 1–2 mg | On-demand (SC) | Do not exceed 1 dose per 24 hours or 8 doses per month |
PT-141 works centrally in the brain through melanocortin receptors to stimulate sexual desire and arousal via dopamine release. Viagra and Cialis work peripherally on blood vessel smooth muscle through PDE5 inhibition to facilitate physical response. PT-141 addresses desire (the wanting), while PDE5 inhibitors address mechanics (the physical response). This means PT-141 can be effective in cases where PDE5 inhibitors fail because the underlying issue is desire-related rather than vascular.
Onset is approximately 45 minutes after subcutaneous injection, with peak effects occurring at 1–3 hours. The effects can persist for 6–12 hours. This reflects the time required for melanocortin receptor activation, downstream dopamine release, and establishment of central arousal signaling.
Nausea occurs in approximately 40% of users because melanocortin receptors (particularly MC4R) are expressed in brainstem areas that regulate nausea and emesis. This is a central effect directly related to the same receptor activation that produces the therapeutic arousal response. Nausea is typically mild, transient (30–60 minutes), and often diminishes with repeated use.
PT-141 has reduced but not eliminated melanogenic activity compared to its parent compound melanotan II. Transient skin darkening (hyperpigmentation) occurs in 1–3% of users, typically with repeated dosing. This results from residual MC1R agonism stimulating melanocyte melanin production. The effect is mild and reversible upon discontinuation.
PT-141 is dosed on-demand, not on a daily schedule. The FDA-approved dose is 1.75 mg SC, administered at least 45 minutes before anticipated activity. No more than one dose should be administered in 24 hours, and no more than 8 doses per month. Higher frequency may lead to tachyphylaxis (reduced response) and increased melanocortin side effects.
Need help choosing a peptide?
Try the AI Coach →